• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Camurus

551.00 SEK

+0.64 %

Less than 1K followers

CAMX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.64 %
+2.32 %
+22.23 %
-10.55 %
-9.15 %
-6.93 %
+91.59 %
+172.77 %
+811.86 %

Camurus operates in biotechnology. The company is operated as a research-based pharmaceutical company that develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders and patients with opioid addiction. Camurus runs development projects under its own management and in partnership with international pharmaceutical companies. The company is headquartered in Lund.

Read more
Market cap
33.37B SEK
Turnover
34.37M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
15.7.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Camurus, Audiocast, Q2'26
Webcast15.07.2026 klo 15.00

Camurus, Audiocast, Q2'26

Camurus
Regulatory press release11.06.2026 klo 00.55

Camurus AB: Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly

Camurus
Regulatory press release01.06.2026 klo 18.00

Camurus AB: Camurus announces expansion of Lilly collaboration

Camurus

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release28.05.2026 klo 21.30

Camurus AB: Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2026/2029

Camurus
Regulatory press release28.05.2026 klo 20.00

Camurus AB: Resolutions at the annual general meeting 2026 in Camurus

Camurus
Press release21.05.2026 klo 11.00

Camurus AB: Camurus to present at Jefferies Global Healthcare Conference

Camurus
Press release13.05.2026 klo 15.47

Redeye: Camurus (Q1 review): Revenues Below Expectations, but Robust Patient Growth

Camurus
Camurus, Audiocast, Q1'26
Webcast12.05.2026 klo 15.00

Camurus, Audiocast, Q1'26

Camurus
Regulatory press release12.05.2026 klo 08.00

Camurus AB: Camurus' Interim Report January-March 2026

Camurus
Regulatory press release29.04.2026 klo 11.00

Camurus AB: Camurus Annual Report for 2025

Camurus
Regulatory press release24.04.2026 klo 09.00

Notice of annual general meeting 2026 in Camurus AB (publ)

Camurus
Regulatory press release31.03.2026 klo 08.00

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Regulatory press release27.02.2026 klo 16.30

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Press release18.02.2026 klo 12.25

Redeye: Camurus (Q4 review): Temporary UK Setback

Camurus
Press release17.02.2026 klo 09.00

Camurus AB: Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer

Camurus
Camurus, Audiocast, Q4'25
Webcast12.02.2026 klo 15.00

Camurus, Audiocast, Q4'25

Camurus
Regulatory press release12.02.2026 klo 08.00

Camurus AB: Camurus' Full Year Report 2025

Camurus
Regulatory press release09.01.2026 klo 16.10

Camurus AB: Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

Camurus
Regulatory press release30.12.2025 klo 08.00

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Press release16.12.2025 klo 12.30

Camurus AB: Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism

Camurus